Your shopping cart is currently empty

MPI8 (TG0205221) TFA is an inhibitor specifically designed for SARS-CoV-2 main protease (MPro), exhibiting significant antiviral activity. Its antiviral effects are achieved through the dual and selective inhibition of both SARS-CoV-2 MPro and the host cell's cysteine protease L (cathepsin L). MPI8 TFA is applicable for clinical research related to COVID-19.
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | MPI8 (TG0205221) TFA is an inhibitor specifically designed for SARS-CoV-2 main protease (MPro), exhibiting significant antiviral activity. Its antiviral effects are achieved through the dual and selective inhibition of both SARS-CoV-2 MPro and the host cell's cysteine protease L (cathepsin L). MPI8 TFA is applicable for clinical research related to COVID-19. |
| Synonyms | TG0205221 TFA |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.